Table 2.
Survival results per Pan-Immune-Inflammation value group.
| Outcome | Whole cohort (N = 89) | PIV < 417 (N = 36) | PIV ≥417 (N = 53) | p-value |
|---|---|---|---|---|
| Metabolic response rates, n (%) | ||||
| CMR | 18 (20.2) | 12 (33.3) | 6 (11.3) | 0.002 |
| PMR | 9 (10.1) | 6 (16.7) | 3 (5.7) | |
| SMD | 3 (3.4) | 2 (5.6) | 1 (1.9) | |
| PMD | 59 (66.3%) | 16 (44.4) | 43 (81.1) | |
| Progression-free survival | ||||
| Median (mo.) | 11.0 | 18.0 | 8.9 | <0.001 |
| 1-year (%) | 43.5 | 61.1 | 31.4 | |
| 2-years (%) | 25.4 | 34.8 | 18.8 | |
| 5-years (%) | 14.5 | 21.1 | 4.7 | |
| Overall survival | ||||
| Median (mo.) | 18.0 | 25.0 | 14.0 | <0.001 |
| 1-year (%) | 65.1 | 75.0 | 60.4 | |
| 2-years (%) | 35.9 | 51.9 | 25.3 | |
| 5-years (%) | 22.3 | 43.1 | 10.7 | |
PIV: pan-immune-inflammation value; CMR: complete metabolic response; PMR: partial metabolic response; SMD: stable metabolic disease; PMD: progressive metabolic disease; mo.: months.